Atai Life Sciences N.V. (ATAI) Advances Psychedelic Therapies for Mental Health, Drawing Investor Spotlight

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Atai Life Sciences N.V. is one of them.

Atai Life Sciences N.V. (NASDAQ:ATAI), headquartered in the Netherlands, is a clinical-stage biopharmaceutical company developing innovative treatments for mental health disorders, including depression, anxiety, and substance use disorders. The company leverages a data-driven platform to advance psychedelic-derived and other novel therapeutics aimed at transforming mental health care.

In September 2025, Atai Life Sciences N.V. (NASDAQ:ATAI) actively participated in major investor conferences, including the Cantor Global Healthcare and H.C. Wainwright Annual Global Investment Conferences, demonstrating strong engagement with investors. The company also strengthened its governance by appointing two independent directors, signaling a focus on long-term strategic planning.

ATAI’s stock has surged over 250% year-to-date, recently trading near a 52-week high of $4.72, supported by robust revenue growth of 163.4%. Analysts remain optimistic, with a strong buy consensus.

The business continues advancing key programs, including PCN-101, an R-ketamine derivative for treatment-resistant depression, and RL-007 for schizophrenia subpopulations.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.